1 July 2024 - Alteogen announced on 1 July that its subsidiary, Altos Biologics submitted a marketing authorisation application to the EMA for an aflibercept biosimilar ALT-L9, developed by Alteogen.

The Phase 3 clinical trial for ALT-L9 commenced with initial clinical trial approval in 2022, involving over 400 subjects across 12 countries.

Read Alteogen press release